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osting by EAbstract Familial Mediterranean fever (FMF) is an autosomal recessive disease which is charac-
terized by recurrent fever and inﬂammation of serous membranes. A Chilean FMF patient was
investigated for MEFV mutations. After DNA extraction, exons 3, 5, 10 and 30UTR region of
MEFV gene were analyzed by DNA sequencing while E148Q and R202Q mutations of exon 2 were
detected by RFLP. A novel missense mutation, A511V (c.1532C>T, p.Ala511Val), was found in a
heterozygous state in exon 5 ofMEFV gene. Also, R202Q (c.605G>A, p.Arg202Gln) was detected
in heterozygous state. R202Q was of clinical value in the diagnosis of FMF when combined with a
disease causing mutation. In this patient, A511V was detected in compound heterozygous state with
R202Q and this association may play an important role in FMF.
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lsevier1. Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive
disease which is characterized by recurrent fever and inﬂam-
mation of serous membranes (peritoneum, synovium and
pleura [1]). FMF, having the most frequent occurrence be-
tween hereditary periodic diseases, was ﬁrst identiﬁed as a
clinic entity by Siegal in 1945 [2]. The most important compli-
cation of FMF is amyloidosis. Colchicine has been used in
treatment since 1972 [3]. It reduced the frequency and severity
of FMF attacks and prevented the development of amyloidosis
[4–6].
FMF most commonly occurs in Mediterranean populations
especially in Jews, Turks, Arabs and Armenians [1,7]. Although
the disease is seen in other populations rarely, it was deﬁned
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Figure 2 PCR–RFLP of novel MEFV mutation A511V ana-
lyzed by agarose gel electrophoresis. PCR products 526 bp of exon
5 were digested by HhaI restriction endonuclease and band
proﬁles were examined in 3% agarose gel. After digestion, 361,
199, 165 and 162 bp fragments were observed in heterozygosity
whereas 199, 165 and 162 bp fragments in wild-type. M: X174
DNA-HaeIII Marker, 1–2: Uncut, 3–4: wild-type, 5–6: Heterozy-
gous (these are the same sample).
22 N. Akar et al.in Greeks, Italians, Germans, Polishes, Australians, Cubans,
Belgians, Brazilians [8], and also Egyptians [9]. The prevalence
was reported as 1/256–1/500 in non-Ashkenazi Jews [10] and as
1/1073 in Turks [11]. On the other hand carrier frequency was
estimated in North African Jews, Ashkenazi Jews, Armenians
and Turks as 1/5, 1/11, 1/7 and 1/5, respectively [10,12,13].
No data are available regarding the proportion of MEFV
mutation in Chilean FMF patients.
MEFV gene, responsible for FMF, in 16p13.3 [14], was
cloned by International FMF Consortium and French FMF
Consortium independently and indicated that it comprises 10
exons, including 3505 nucleotides and 15 kb length. The pro-
tein encoded by MEFV was called as pyrin/marenostrin which
contains 781 amino acids [15,16]. Its expression in neutrophils
and functions in inﬂammation were shown in studies [17].
After cloning of the gene, M694V, M680I and V726A
mutations were the ﬁrst to be determined in exon 10 [15,16].
To date, more than 180 mutations and/or polymorphisms re-
lated to FMF were identiﬁed in the MEFV gene [18].
A patient from Chilie, diagnosed as FMF case according to
the Tel-Hashomer criteria was investigated for MEFV muta-
tions. The patient had periodic fever, abdominal pain lasting
for several years.
2. Subjects and methods
Blood sample of the patient was transferred from Chile to An-
kara/Turkey. DNA was extracted from peripheral blood lym-
phocytes according to standard procedures. Exons 3, 5, 10 and
30UTR were analyzed by DNA sequencing whereas E148Q
and R202Q mutations in exon 2 were detected by Restriction
Fragment Length Polymorphism (RFLP) method. For poly-
merase chain reactions (PCR) of exon 2, 3, 5 and 10-30UTR,
F:50-ATCTTGGGCCCTAAACGTGG-30 and R:50-TCC-
TTCAGGTCCGCAGATGC-30, F:50-TCTGTGTAAGCAA-
CTTGGGTTTG-30 and R:50-TTGGGAAAATGAAGT
AAGGCCC-30, F:50-TATCGCCTCCTGCTCTGGAATC-30
and R:50-CACTGTGGG TCACCAAGACCAAG-30, F:50-
GAGGTGGACGTTGGAGACAA-30 and R:50-TCCT CCT-
CTGAAATCCATGG-30 primers were used and 658, 480,
526, and 614 bp fragments were ampliﬁed, respectively. The
amplicons of exon 2 were analyzed using Eco88I and PvuIIFigure 1 Electrophoregram of the new A511V MEFV variant. (a)
converts alanine to valine exchange in codon 511. Also 1530 C > T prestriction endonucleases (Fermentas, Lithuania) for muta-
tions E148Q and R202Q. For sequencing, PCR products were
puriﬁed using a PCR puriﬁcation kit (Metis, Turkey) and then
analyzed by automated ﬂuorescence DNA sequencing method
(CEQ8000XL, Beckman Coulter, USA) [19,20].
3. Results
A new variant, the A511V (Alanine–Valine) missense muta-
tion, caused by a C > T transition at nucleotide 1532 in exon
5, which results in a alanine–valine exchange at codon 511, was
found in the heterozygous state by sequencing (Fig. 1), and
also this mutation was conﬁrmed by RFLP. Ampliﬁed
526 bp product digested with HhaI (Fermentas, Lithuania) at
37 C and subjected to 3% agarose gel electrophoresis. After
digestion, in sample of wild type there were 3 fragments
(199, 165 and 162 bp) while 4 fragments in heterozygote sam-
ple (361, 199, 165 and 162 bp) (Fig. 2). On the other hand,
R202Q mutation in exon 2, R314R in exon 3, E474E,
Q476Q and D510D polymorphisms in exon 5 were detected
in heterozygous state. But no mutation was found after
sequencing of other exons and 30UTR of the MEFV gene.Wild-type (b) The C > T transition at nucleotide 1532 in exon 5
olymorphism is seen in heterozygous state (nt: nucleotide).
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Molecular analysis of the MEFV gene revealed that a novel
missense mutation A511V, located in exon 5 of the gene, was
present in the heterozygous state. It causes amino acid replace-
ment of alanine to valine. Polymorphisms and FMF causing
mutations have been described in exon 5 suggesting the func-
tional importance of this domain [21].
E474E (1422GA), Q476Q (1428AG), and D510D (1530TC)
polymorphisms in exon 5 and R314R polymorphism in exon 3
were ﬁrst deﬁned by Bernot and colleagues (1998) and has been
used as markers in haplotype analysis [22,23]. Cazeneuve et al.
(1999) showed that these three polymorphisms were associated
in cis position, in addition to R501R (1503CT) polymorphism
[24]. Also, Aldea and his colleagues (2004) constituted haplo-
types including 1422GA, 1428AG and 1530TC polymorphisms
[21].
R202Q in exon 2 ofMEFV gene was ﬁrst identiﬁed by Bernot
et al. (1998) and it has been proposed to be a common polymor-
phism [22]. Additionally, in FMF database, R202Q was indi-
cated as a polymorphism in linkage disequilibrium with
M694V [18]. In a study of 26 Greek FMF patients, R202Q
homozygosity has been shown in 4 patients but was not detected
in 60 healthy controls and statistically signiﬁcant difference was
observedbetween the twogroups.R202Qgene alterationmaybe
a mutation more than a polymorphism and because of the het-
erozygote controls, dose-dependent effectmayoccur in homozy-
gous FMFpatients [25]. In the following years, homozygosity of
R202Qwas reported to be associated with the disease and could
be a mutation but has not been mentioned the relation with the
M694V mutation [26]. Miyoshi et al. (2008) reported E148Q/
R202Q compound heterozygosity in a Japanese patient which
may be responsible for the disease [27]. Although, R202Q heter-
ozygosity was detected in 163 healty Japanese controls of 170,
homozygosity could not be detected [28]. In our previous study,
we found that there is onemore haplotype,whichwasnot in link-
age disequilibriumwithM694V. This result showed that R202Q
might be associated with the disease at least in some FMF pa-
tients. R202 homozygosity could not be detected in our control
group but, high frequency of heterozygosity showed that it has
no effect when it is in heterozygous state. However, when carry-
ing R202Q in compound heterozygous with another disease
causing mutation, the clinical spectrum appears [29]. So, this
emphasizes importance of R202Q for diagnosis. Also our Chil-
ean patient carries R202Q and A511V in compound heterozy-
gote state. This association may create a defect on protein
function and could play an important role in FMF progression.
We were not able to screen A511V mutation in Chilean
population. Five hundred sixteen Turkish & Egyptian FMF
patients were analyzed for exon 5 of MEFV gene by sequenc-
ing and A511V was not present. In conclusion, our results
show that compound heterozygosity of R202Q and A511V
may have a role in expression of the clinical ﬁndings. The rel-
evance of the novel mutation with the disease should be con-
ﬁrmed by studying with FMF in large patient groups and by
functional studies.
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